Skip to main content
L

Lionco Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 603669 ISIN · CNE1000022R8 LEI · 300300EU7LBPZ25TZO93 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,202 across all filing types
Latest filing 2024-06-17 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603669

About Lionco Pharmaceutical Group Co.,Ltd.

Lionco Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and sale of chemical drug preparations. The company specializes in a diverse range of therapeutic areas, including anti-infectives, digestive system treatments, cardiovascular health, and respiratory medicine. Its product portfolio primarily consists of high-end generic drugs, featuring formulations such as freeze-dried powder for injection, small-volume injections, and solid oral dosages. Lionco emphasizes technological innovation and quality control to provide clinical solutions for various medical conditions. The group operates multiple manufacturing facilities and maintains a comprehensive distribution network to serve healthcare providers and patients.

Recent filings

Filing Released Lang Actions
关于“灵康转债”预计满足转股价格修正条件的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Lingkang Pharmaceutical Group Co., Ltd. regarding the expected triggering of the convertible bond's conversion price adjustment conditions. It details the bond issuance, the terms for conversion price adjustment, the current stock price situation, and the company's obligations to disclose and possibly adjust the conversion price. The document is an announcement about a potential price adjustment event related to convertible bonds, not a financial report, earnings release, or detailed investor presentation. It does not contain financial statements or detailed financial analysis but rather regulatory disclosure about bond terms and potential price adjustments. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as convertible bond price adjustments.
2024-06-17 Chinese
中信证券股份有限公司关于《关于灵康药业集团股份有限公司2023年年度报告的信息披露监管工作函》相关问题的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from a sponsoring institution (中信证券股份有限公司) regarding regulatory inquiries about the 2023 annual report of 灵康药业集团股份有限公司. It discusses the progress and issues related to a convertible bond fundraising project, including investment usage, project delays, market environment, and reasons for project termination. The document references the 2023 annual report and provides extensive financial and operational details related to the company's fundraising and project status. It is not merely an announcement or a brief summary but contains substantive financial and operational analysis related to the annual report period. Therefore, this document is best classified as an Audit Report / Information (AR) because it is a standalone regulatory verification and audit-related opinion concerning the annual report disclosures, rather than the annual report itself or a simple announcement. FY 2023
2024-06-17 Chinese
关于“灵康转债”2024年第一次债券持有人会议决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement regarding the resolution of the 2024 first bondholders meeting for a convertible bond issued by Lingkang Pharmaceutical Group Co., Ltd. It details the meeting attendance, voting results, legal witness statements, and confirms the validity and legality of the meeting and its resolutions. There is no financial report or detailed financial data presented, nor is it a full annual or interim report. The document is a formal announcement of the voting results from a bondholders meeting, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short (1488 characters), and it is not merely announcing the publication of a report but providing the actual voting results and meeting details. Therefore, the correct classification is DVA with high confidence.
2024-06-16 Chinese
2024年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 2024 first extraordinary general meeting of shareholders of Lingkang Pharmaceutical Group Co., Ltd. It details the meeting date, location, attendance, voting results, and legal opinions on the meeting's legality. There is no financial data or report content, only the voting results and procedural information. This fits the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and focused on voting outcomes, not a full report or presentation.
2024-06-16 Chinese
北京市中伦（深圳）律师事务所关于灵康药业集团股份有限公司2024年第一次临时股东大会的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening and procedures of a 2024 first extraordinary general meeting (临时股东大会) of Lingkang Pharmaceutical Group Co., Ltd. It details the legality of the meeting's notice, the qualifications of attendees, the voting procedures, and the voting results. The document does not contain financial statements or management discussion but focuses on the legal compliance and validity of the shareholder meeting and its resolutions. It is not an announcement of voting results per se, but a legal opinion on the meeting's conduct and results. Given the nature of the document as a legal opinion letter related to a shareholder meeting, it best fits the category of Regulatory Filings (RNS), which covers miscellaneous regulatory announcements and compliance documents that do not fit other categories. The document length is short (3160 characters), and it is not a report publication announcement or a direct voting result announcement. Therefore, the classification is RNS with high confidence.
2024-06-16 Chinese
关于“灵康转债”可选择回售的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Lingkang Pharmaceutical Group Co., Ltd. regarding the optional repurchase (回售) of its convertible bonds (灵康转债). It details the repurchase price, repurchase period, payment date, and related trading suspension information. The document is a formal notice to bondholders about their rights and procedures for repurchasing bonds, including terms and conditions. It does not contain financial statements, audit information, or detailed financial results. It is not a report but an announcement about a capital/financing activity related to convertible bonds. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is 1951 characters, which is consistent with an announcement rather than a full report.
2024-06-16 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.